Daiichi Sankyo Company, Limited DSKYF
18.08 USD -0.06 (-0.33%)
Regular-session close
19.25 Day range 19.25
14.76 52-week range 24.46
- YTD
- -15.91%
- 1 year
- -17.25%
News
businesswire.com Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the second quarter of fiscal year 2026, ending September 30, 2026. “Strong revenue growth continues in the second…
businesswire.com Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union MUNICH--(BUSINESS WIRE)--The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination…
benzinga.com Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1 Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1First EU…
businesswire.com Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO.
reuters.com AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination AstraZeneca and Daiichi Sankyo have entered into a clinical collaboration with Summit Therapeutics to test their cancer drug, Datroway, in combination with Summit's ivonescimab across multiple…
reuters.com Merck, Daiichi Sankyo withdraw US application for lung cancer drug Merck and Daiichi Sankyo have voluntarily withdrawn their US application seeking accelerated approval for their experimental lung cancer therapy, the drugmakers said on Friday.
businesswire.com Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization.
businesswire.com Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026. “Daiichi Sankyo delivered strong revenue growth in the…
seekingalpha.com Daiichi Sankyo Company, Limited (DSNKY) Q4 2026 Earnings Call Transcript Daiichi Sankyo Company, Limited (DSNKY) Q4 2026 Earnings Call Transcript
seekingalpha.com Daiichi Sankyo Company, Limited (DSKYF) Q1 FY2025 Earnings Call Transcript Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 FY2025 Earnings Call July 31, 2025 4:30 AM ET Company Participants Asakura - VP of Corporate Communications Koji Ogawa - Senior Executive Officer and…
seekingalpha.com Daiichi Sankyo Company, Limited (DSKYF) FY2024 Earnings Call Transcript Daiichi Sankyo Company, Limited (OTCPK:DSKYF) FY2024 Earnings Conference Call April 25, 2025 2:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Hiroyuki Okuzawa -…
seekingalpha.com Daiichi Sankyo Company, Limited (DSKYF) Q3 2024 Earnings Call Transcript Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q3 2024 Earnings Call Transcript January 31, 2025 1:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Department Koji Ogawa…
seekingalpha.com Daiichi Sankyo Company, Limited (DSKYF) Q1 2024 Earnings Call Transcript Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 2024 Earnings Conference Call July 31, 2024 5:00 AM ET Company Participants Toshinori Agatsuma - Head of R&D Division Koji Ogawa - Head of Global…
benzinga.com 5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.